Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Apple Turns 50: From Garage Startup to AI Crossroads 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
NEW YORK, July 13, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the U.S. District Court for the Southern District of New York on behalf of investors who purchased Neurotrope, Inc. ("Neurotrope") (NASDAQ:NTRP) securities between January 7, 2016, and April 28, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/neurotrope-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the class period, Neurotrope issued materially false and misleading statements and/or failed to disclose material information concerning the efficacy of its lead product candidate, Bryostatin-1. On May 1, 2017, Neurotrope issued a press release announcing “positive top-line results” of the pivotal Phase 2b trials of Bryostatin-1, noting “improvement in patients with moderate to severe Alzheimer’s disease.” However, the underlying trial data contradicts these representations, as the top-line data relating to the 20 microgram dose of Bryostatin-1 failed to produce results that were statistically significant. In addition, Neurotrope failed to disclose statements regarding the efficacy of the 40 microgram dose with regard to its primary and secondary endpoints. Upon this news, shares of Neurotrope fell from a close of $18.81 on April 28, 2017, to a close of $6.97 per share on May 1, 2017.
If you suffered a loss in Neurotrope you have until July 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/neurotrope-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
